Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III first-line study of SHR-8068 + adebrelimab + platinum-based chemotherapy versus durvalumab + platinum-based chemotherapy in advanced biliary tract cancer
CTR20254313Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of CS1002 in biliary cancer (2 arms), sponsored by Suzhou Shengdiya Biopharmaceuticals. Primary endpoint: Overall survival. Started Jan 2026; status: active.
02
Drugs
CS1002
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20254313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254313.